Blay, J. Y., Le Cesne, A., Verweij, J., Scurr, M., Seynaeve, C., Bonvalot, S., Hogendoorn, P., Jimeno, J., Evrard, V., van Glabbeke, M., Judson, I. (2004) A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours. EUROPEAN JOURNAL OF CANCER, 40 (9). pp. 1327-1331. ISSN 0959-8049

Full text not available from this repository.

Abstract

A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours Primary or secondary resistance to imatinib may occur in patients with gastrointestinal stromal tumours (GISTs) while these tumours have repeatedly been shown to be highly resistant to conventional doxorubicin- and ifosfamide-containing regimens. The investigation of new drugs is therefore warranted in GIST. A phase 11 study was conducted between May 1999 and November 2000 in eight centres of the EORTC STBSG group to establish the efficacy and safety of ET743 ('Yondelis') in GIST previously untreated with cytotoxic chemotherapy before the imatinib era. ET-743 was given was given at 1.5 mg/m(2) per course as a 24-h continuous intravenous infusion every 3 weeks. Twenty-eight patients were included, 16 mates and 12 females. Median age was 54 years (range 25-73 years). Median performance status was 0 (range 0-1). 17 (63%), 4 (12%) and 7 (25%) patients, received 0-2, 3-5, and greater than or equal to 6 courses of ET-743, respectively. The best response was stable disease in 9 (33%) patients, and disease progression in IS patients (67%), with a median time to disease progression and overall survival of 51 days and 589 days, respectively. The treatment was well tolerated: there were grades 3-4 neutropenia, thrombocytopenia, and transaminase increases in 13 (48%), 1 (4%) and 16 (59%) patients, respectively. There were no toxic deaths. ET-743 at this dose and schedule is not an effective treatment for advanced GIST. (C) 2004 Elsevier Ltd. All rights reserved.

Item Type:	Article
Authors (ICR Faculty only):	Judson, Ian
All Authors:	Blay, J. Y., Le Cesne, A., Verweij, J., Scurr, M., Seynaeve, C., Bonvalot, S., Hogendoorn, P., Jimeno, J., Evrard, V., van Glabbeke, M., Judson, I.
Uncontrolled Keywords:	Bone sarcoma group; soft-tissue sarcomas; tyrosine kinase inhibitor; kit gene; c-kit; european-organization; germline mutation; imatinib mesylate; diagnosis; ecteinascidin-743
Research teams:	ICR divisions > Cancer Therapeutics > Clinical Pharmacology & Trials (including Drug Metabolism & Pharmacokinetics Group) Clinical Units > Sarcoma Unit
Depositing User:	EPrints Services
Date Deposited:	10 Aug 2007 20:48
Last Modified:	15 Apr 2015 15:35
URI:	http://publications.icr.ac.uk/id/eprint/1859

Actions (login required)

View Item